Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at AMCP Nexus 2018
22. Oktober 2018 08:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the Academy of Managed Care Pharmacy’s AMCP...
Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at ASN Kidney Week 2018
09. Oktober 2018 16:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the American Society of Nephrology (ASN) Kidney...
Relypsa Announces Appointment of Patrick Treanor as President
01. Oktober 2018 08:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced the appointment of Patrick Treanor as president on an interim basis, effective...
Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food
08. Mai 2018 08:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that the United States (U.S) Food and Drug Administration (FDA) approved a...
Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders
16. April 2018 16:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that it has awarded three research grants to supplement institutional funding...
Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at the National Kidney Foundation 2018 Spring Clinical Meetings
11. April 2018 08:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced results from a pooled analysis of three clinical trials evaluating the effects...
Relypsa Secures Loan Facility of Up to $35 Million
02. Juni 2014 08:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., June 2, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced it has secured a loan facility of up to $35 million with Oxford Finance...
Relypsa Names Sylvia R. Wheeler V.P. Investor Relations and Corporate Affairs
02. April 2014 09:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 2, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the appointment of Sylvia R. Wheeler to the position of Vice...